WADA 2027 List names peptides as S0 examples

The World Anti-Doping Agency published the 2027 List of Prohibited Substances and Methods after its Executive Committee approved it on September 10, 2026 ^[1]. WADA's resource page for the List records a publication date of September 21, 2026 ^[2]. The List takes effect on January 1, 2027 ^{[1, 2]}.

S0 now names peptides

S0 covers any pharmacological substance that later sections of the List do not address and that no governmental regulatory health authority has approved for human therapeutic use ^{[4, 5]}. The 2026 List already named BPC-157 as an S0 example, along with designer drugs and substances approved only for veterinary use ^[5]. The 2027 List (tracked-changes text) adds the word "peptides" to those examples ^[4]. WADA's 2027 modification note says many peptides not approved for human use meet the Code criteria for the List and fall under S0 or other classes such as S2 or S4, and that a peptide that is not named may still be prohibited ^[3].

The 2027 modification note does not list changes to S2 peptide hormones, growth factors, related substances, and mimetics ^[3]. The 2027 tracked List still names, among others, kisspeptin, AOD-9604, CJC-1295, sermorelin, tesamorelin, ipamorelin, GHRP-2 and GHRP-6, ibutamoren (MK-677), and TB-500 under S2 ^[4].

GLP-1 agonists stay on monitoring

WADA says the status of glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide and tirzepatide, remains unchanged for 2027 pending further data ^[1]. They are not on the Prohibited List. The 2027 Monitoring Program lists GLP-1 agonists, naming semaglutide and tirzepatide, in and out of competition ^[6]. The 2026 Monitoring Program listed "Markers of Semaglutide and Tirzepatide" for the same window ^[7]. Dermorphin and its analogs were on the 2026 Monitoring Program under narcotics and were removed for 2027 after WADA said enough information had been collected ^{[3, 6, 7]}.

Peptides in this update

• BPC-157: FDA status, research and uses
• TB-500 and Thymosin Beta-4: FDA status, research and uses
• AOD-9604: FDA status, research and uses
• CJC-1295: FDA status, research and uses
• Sermorelin: FDA status, research and uses
• Tesamorelin: FDA status, research and uses
• Ipamorelin: FDA status, research and uses
• GHRP-2 and GHRP-6: FDA status, research and uses
• MK-677 (Ibutamoren): FDA status, research and uses
• Kisspeptin: FDA status, research and uses
• Semaglutide: FDA status, research and uses
• Tirzepatide: FDA status, research and uses

More news

• DEA telemedicine flexibilities run through 2026
• FDA advisers review seven peptides for compounding
• FDA proposes keeping GLP-1s off the 503B bulks list
• FDA warns 30 telehealth firms over compounded GLP-1 ads
• HHS interim policy covers 6 peptides for compounding
• Most peptides leave FDA's Category 2 list

Status of every peptide

• FDA Peptide Status Tracker

Sources

1. WADA: WADA publishes 2027 Prohibited List
2. WADA: 2027 Prohibited List (resource page, 21 Sep 2026)
3. WADA: 2027 Summary of Major Modifications and Explanatory Notes (PDF)
4. WADA: 2027 Prohibited List, redline version (PDF)
5. WADA: 2026 Prohibited List (PDF)
6. WADA: 2027 Monitoring Program (PDF)
7. WADA: 2026 Monitoring Program (PDF)

Updated October 26, 2026. Educational information, not medical advice.